Table 2.
Summary of effectiveness outcomes.
| Before treatment | After treatment | p value | |
|---|---|---|---|
| FEV1% of predicted, mean (SD) | 73.68 (21.43) | 82.94 (21) | 0.0069 |
| FEV1 (L), mean (SD) | 2.11 (0.748) | 2.33 (0.70) | 0.0224 |
| FEV1/FVC, mean (SD) | 69.48 (15.52) | 69.31 (11.23) | Ns |
| ACT, mean (SD) | 13.65 (4.54) | 21.29 (4.49) | <0.0001 |
| Blood eosinophils, median (IQR) | 791 (420–1300) | 80 (43–109) | <0.0001 |
| OCS therapy dependent, n (%) | 21 (67.7) | 5 (16.1) | <0.0001 |
| OCS mg/30days, median (IQR) | 56.25 (0–112.5) | 0 (0–0) | 0.0012 |
| Number of exacerbations/year, median (IQR) | 6 (4–12) | 0 (0–1) | <0.0001 |
SD, standard deviation; IQR, interquartile range; OCS, oral corticosteroid; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ACT, asthma control test